[go: up one dir, main page]

CA2672876A1 - Traitement a base d'anti-arythmisants et d'acides gras omega-3 et produit mixte obtenu a partir de ceux-ci - Google Patents

Traitement a base d'anti-arythmisants et d'acides gras omega-3 et produit mixte obtenu a partir de ceux-ci Download PDF

Info

Publication number
CA2672876A1
CA2672876A1 CA002672876A CA2672876A CA2672876A1 CA 2672876 A1 CA2672876 A1 CA 2672876A1 CA 002672876 A CA002672876 A CA 002672876A CA 2672876 A CA2672876 A CA 2672876A CA 2672876 A1 CA2672876 A1 CA 2672876A1
Authority
CA
Canada
Prior art keywords
omega
pharmaceutical composition
antiarrhythmic agents
fatty acids
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002672876A
Other languages
English (en)
Inventor
George Bobotas
Roelof M.L. Rongen
Abdel A. Fawzy
Ihor Terleckyj
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Reliant Pharmaceuticals Inc
Original Assignee
Reliant Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reliant Pharmaceuticals Inc filed Critical Reliant Pharmaceuticals Inc
Publication of CA2672876A1 publication Critical patent/CA2672876A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CA002672876A 2006-10-13 2007-10-15 Traitement a base d'anti-arythmisants et d'acides gras omega-3 et produit mixte obtenu a partir de ceux-ci Abandoned CA2672876A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85129406P 2006-10-13 2006-10-13
US60/851,294 2006-10-13
PCT/US2007/021963 WO2008063323A2 (fr) 2006-10-13 2007-10-15 Traitement à base d'anti-arythmisants et d'acides gras oméga-3 et produit mixte obtenu à partir de ceux-ci

Publications (1)

Publication Number Publication Date
CA2672876A1 true CA2672876A1 (fr) 2008-05-29

Family

ID=39430253

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002672876A Abandoned CA2672876A1 (fr) 2006-10-13 2007-10-15 Traitement a base d'anti-arythmisants et d'acides gras omega-3 et produit mixte obtenu a partir de ceux-ci

Country Status (10)

Country Link
EP (1) EP2083802A2 (fr)
JP (1) JP2010506841A (fr)
KR (1) KR20090086078A (fr)
CN (1) CN101557805A (fr)
AU (1) AU2007322291A1 (fr)
BR (1) BRPI0719183A2 (fr)
CA (1) CA2672876A1 (fr)
EA (1) EA200970374A1 (fr)
MX (1) MX2009003928A (fr)
WO (1) WO2008063323A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
EA020237B1 (ru) * 2008-08-07 2014-09-30 СПА СОЧЬЕТА'ПРОДОТТИ АНТИБИОТИЧИ С.п.А. Способ снижения смертности от сердечно-сосудистых событий
WO2010127103A1 (fr) * 2009-04-29 2010-11-04 Amarin Pharma, Inc. Composition pharmaceutique stable et ses procédés d'utilisation
SG175390A1 (en) * 2009-04-29 2011-12-29 Amarin Corp Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
SI2443246T1 (en) 2009-06-15 2018-05-31 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
ES2363965B1 (es) 2009-11-20 2013-01-24 Gp Pharm S.A. Cápsulas de principios activos betabloqueantes y ésteres de ácidos grasos poliinsaturados.
ES2363964B1 (es) 2009-11-20 2012-08-22 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados.
CN102188417A (zh) * 2010-03-19 2011-09-21 江苏恒瑞医药股份有限公司 决奈达隆药物组合物
FR2967067A1 (fr) 2010-11-10 2012-05-11 Sanofi Aventis Composition pharmaceutique et forme galenique a base de dronedarone et son procede de preparation
EP2755646A4 (fr) * 2011-09-15 2015-06-10 Omthera Pharmaceuticals Inc Méthodes et compositions pour traiter, inverser, inhiber ou prévenir la résistance à la thérapie antiplaquettaire
WO2013116738A1 (fr) * 2012-02-03 2013-08-08 Cardeus Pharmaceuticals, Inc. Formulations de médicament
EP2853263B1 (fr) 2012-05-22 2021-12-01 Kuhnil Pharm. Co. Ltd. Forme à enrobage multicouche de composition pharmaceutique à administration par voie orale contenant un acide gras oméga-3 ou un ester alkylique de celui-ci et un médicament à base de statine
TR201503136A2 (tr) * 2015-03-16 2016-09-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dronedaron ve esansiyel yağ asitlerinin farmasötik kompozisyonları.
US20170128480A1 (en) * 2015-11-09 2017-05-11 Max A. Cayo Cardiac Glycosides for the Treatment of Hypercholesterolemia
US20190054184A1 (en) * 2016-02-12 2019-02-21 The General Hospital Corporation Targeting Macrophages to Modulate Electrical Conduction in the Heart
DK3618847T3 (da) 2017-05-05 2021-05-25 Boston Medical Ct Corp GAP-junction-modulatorer af intercellulær kommunikation og deres anvendelse til behandling af diabetisk øjensygdom
US20210030733A1 (en) * 2018-04-16 2021-02-04 Alsar Ltd Partnership Compositions and methods for sustained release of flecainide
HUE067138T2 (hu) 2018-09-24 2024-10-28 Amarin Pharmaceuticals Ie Ltd Módszerek kardiovaszkuláris események veszélyének csökkentésére egy alanyban
CN116350616A (zh) 2019-11-12 2023-06-30 阿马里纳药物爱尔兰有限公司 降低心房纤颤和/或心房扑动受试者心血管事件风险的方法
US11986452B2 (en) 2021-04-21 2024-05-21 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2893866B2 (ja) * 1990-05-25 1999-05-24 日本油脂株式会社 抗不整脈薬
US5840329A (en) * 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
GB0120415D0 (en) * 2001-08-22 2001-10-17 Isis Innovation Palatable high fat composition
ITMI20020731A1 (it) * 2002-04-08 2003-10-08 Ibsa Inst Biochimique Sa Composizioni farmaceutiche per acido acetilsalicilico e oli omega-3

Also Published As

Publication number Publication date
WO2008063323A2 (fr) 2008-05-29
EA200970374A1 (ru) 2009-10-30
EP2083802A2 (fr) 2009-08-05
JP2010506841A (ja) 2010-03-04
AU2007322291A1 (en) 2008-05-29
CN101557805A (zh) 2009-10-14
MX2009003928A (es) 2009-09-21
KR20090086078A (ko) 2009-08-10
WO2008063323A3 (fr) 2008-12-31
BRPI0719183A2 (pt) 2014-06-03

Similar Documents

Publication Publication Date Title
CA2672876A1 (fr) Traitement a base d'anti-arythmisants et d'acides gras omega-3 et produit mixte obtenu a partir de ceux-ci
US20070196465A1 (en) Treatment with dihydropyridine calcium channel blockers and omega-3 fatty acids and a combination product thereof
US20070036862A1 (en) Treatment with azetidinone-based cholesterol absorption inhibitors and omega-3 fatty acids and a combination product thereof
US8784886B2 (en) Coating capsules with active pharmaceutical ingredients
US9370493B2 (en) Coated capsules and tablets of a fatty acid oil mixture
EP2081550B1 (fr) Revêtement de capsules avec des ingrédients pharmaceutiques actifs
WO2008115529A1 (fr) Compositions comprenant des acides gras omega-3 et des inhibiteurs de la cetp
JP2013508348A5 (fr)
KR20130103521A (ko) 지방산 오일 혼합물, 유리 지방산, 및 스타틴을 포함하는 조성물
WO2008088808A1 (fr) Traitement par médicaments anti-inflammatoires non stéroïdiens et acides gras oméga-3, et produit de combinaison de ceux-ci
WO2008112227A1 (fr) Traitement par nicorandil et acides gras oméga 3 et produit combinant ceux-ci

Legal Events

Date Code Title Description
FZDE Discontinued